.2021 Oct 5;23(12 Suppl 2):iii1-iii105.

doi: 10.1093/neuonc/noab200.

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018

Quinn T Ostrom^{1 2 3 4}, Gino Cioffi^{1 5}, Kristin Waite^{1 5}, Carol Kruchko¹, Jill S Barnholtz-Sloan^{1 5 6}

Affiliations

¹ Central Brain Tumor Registry of the United States, Hinsdale, Illinois, USA.
² Department of Neurosurgery, Duke University School of Medicine, Durham, NC, USA.
³ The Preston Robert Tisch Brain Tumor Center, Duke University School of Medicine, Durham, NC, USA.
⁴ Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA.
⁵ Trans Divisional Research Program (TDRP), Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute, Bethesda, MD, USA.
⁶ Center for Biomedical Informatics & Information Technology (CBIIT), National Cancer Institute, Bethesda, MD, USA.

PMID:34608945
PMCID: PMC8491279
DOI: 10.1093/neuonc/noab200

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018

Quinn T Ostrom et al. Neuro Oncol.2021.

.2021 Oct 5;23(12 Suppl 2):iii1-iii105.

doi: 10.1093/neuonc/noab200.

Authors

Quinn T Ostrom^{1 2 3 4}, Gino Cioffi^{1 5}, Kristin Waite^{1 5}, Carol Kruchko¹, Jill S Barnholtz-Sloan^{1 5 6}

Affiliations

¹ Central Brain Tumor Registry of the United States, Hinsdale, Illinois, USA.
² Department of Neurosurgery, Duke University School of Medicine, Durham, NC, USA.
³ The Preston Robert Tisch Brain Tumor Center, Duke University School of Medicine, Durham, NC, USA.
⁴ Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA.
⁵ Trans Divisional Research Program (TDRP), Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute, Bethesda, MD, USA.
⁶ Center for Biomedical Informatics & Information Technology (CBIIT), National Cancer Institute, Bethesda, MD, USA.

PMID:34608945
PMCID: PMC8491279
DOI: 10.1093/neuonc/noab200

Abstract

The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the CDC and NCI, is the largest population-based registry focused exclusively on primary brain and other central nervous system (CNS) tumors in the United States (US) and represents the entire US population. This report contains the most up-to-date population-based data on primary brain tumors available and supersedes all previous reports in terms of completeness and accuracy and is the first CBTRUS Report to provide the distribution of molecular markers for selected brain and CNS tumor histologies. All rates are age-adjusted using the 2000 US standard population and presented per 100,000 population. The average annual age-adjusted incidence rate (AAAIR) of all malignant and non-malignant brain and other CNS tumors was 24.25 (Malignant AAAIR=7.06, Non-malignant AAAIR=17.18). This overall rate was higher in females compared to males (26.95 versus 21.35) and non-Hispanics compared to Hispanics (24.68 versus 22.12). The most commonly occurring malignant brain and other CNS tumor was glioblastoma (14.3% of all tumors and 49.1% of malignant tumors), and the most common non-malignant tumor was meningioma (39% of all tumors and 54.5% of non-malignant tumors). Glioblastoma was more common in males, and meningioma was more common in females. In children and adolescents (age 0-19 years), the incidence rate of all primary brain and other CNS tumors was 6.21. An estimated 88,190 new cases of malignant and non-malignant brain and other CNS tumors are expected to be diagnosed in the US population in 2021 (25,690 malignant and 62,500 non-malignant). There were 83,029 deaths attributed to malignant brain and other CNS tumors between 2014 and 2018. This represents an average annual mortality rate of 4.43 per 100,000 and an average of 16,606 deaths per year. The five-year relative survival rate following diagnosis of a malignant brain and other CNS tumor was 66.9%, for a non-malignant brain and other CNS tumors the five-year relative survival rate was 92.1%.

PubMed Disclaimer

Figures

**Fig. 1**
Availability by Central Cancer Registry for SEER and NPCR Incidence (2014–2018) and Survival Data (2001–2017).

**Fig. 2**
Overview of CBTRUS Data Edits Workflow, NPCR and SEER, 2014–2018.

**Fig. 3**
A) Average Annual Age-Adjusted Incidence Rates^a (AAAIR) with 95% Confidence Intervals of All Primary Brain and Other CNS Tumors in Comparison To Top Eight Highest Incidence Cancers for Children Age 0–14 Years, Adolescents and Young Adults Age 15–39 Years, and Older Adults Age 40+ Years, CBTRUS Statistical Report: US Cancer Statistics - NPCR and SEER, 2014–2018. B) Average Annual Age-Adjusted Mortality Rates^a with 95% Confidence Intervals of All Primary Brain and Other CNS Tumors in Comparison to Top Five Causes of Cancer Death and Top Three Non-Cancer Causes of Death for Children Age 0–14 Years, Adolescents and Young Adults Age 15–39 Years, and Older Adults Age 40+ Years, CBTRUS Statistical Report: NVSS, 2014–2018.

**Fig. 4**
Distribution^a of All Primary Brain and Other CNS Tumors by Behavior (Five-Year Total=431,773; Annual Average Cases=86,355), CBTRUS Statistical Report: US Cancer Statistics - NPCR and SEER, 2014–2018.

**Fig. 5**
Distribution^a of All Primary Brain and Other CNS Tumors (Malignant and Non-Malignant Combined; Five-Year Total=431,733; Annual Average Cases=86,355), by A) Site and B) Histology, CBTRUS Statistical Report: US Cancer Statistics - NPCR and SEER, 2014–2018.

**Fig. 6**
Distribution^a of Malignant Primary Brain and Other CNS Tumors (Five-Year Total=125,524; Annual Average Cases=25,105), by A) Site and B) Histology, CBTRUS Statistical Report: US Cancer Statistics - NPCR and SEER, 2014–2018.

**Fig. 7**
Distribution^a of All Non-Malignant Primary Brain and Other CNS Tumors (Five-Year Total=306,249; Annual Average Cases=61,250), by A) Site and B) Histology, CBTRUS Statistical Report: US Cancer Statistics - NPCR and SEER, 2014–2018.

**Fig. 8**
Distribution^a of Primary Brain and Other CNS Gliomas (ICD-O-3 histology codes 9380–9384 and 9391–9460) (Five-Year Total=105,729; Annual Average Cases=21,146) by A) Site and B) Histology, CBTRUS Statistical Report: US Cancer Statistics - NPCR and SEER, 2014–2018.

**Fig. 9**
Annual Age-Adjusted Incidence Rates^a of All Primary Brain and Other CNS Tumors by Year and Behavior, CBTRUS Statistical Report: US Cancer Statistics - NPCR and SEER, 2014–2018.

**Fig. 10**
Average Annual Age-Adjusted Incidence Rates^a of All Primary Brain and Other CNS Tumors by Age Group at Diagnosis and Behavior, CBTRUS Statistical Report: US Cancer Statistics - NPCR and SEER, 2014–2018.

**Fig. 11**
Age-Adjusted Incidence Rates^a of Brain and Other CNS Tumors by Selected Histologies and Age Group at Diagnosis A) Age 0–19 Years, B) Age 20+ Years and CBTRUS Statistical Report: US Cancer Statistics - NPCR and SEER, 2014–2018.

**Fig. 12**
Incidence Rate Ratios by Sex (Males:Females) for Selected Primary Brain and Other CNS Tumor Histologies, CBTRUS Statistical Report: US Cancer Statistics - NPCR and SEER, 2014–2018.

**Fig. 13**
Average Annual Age-Adjusted Incidence Rates^a of Malignant and Non-Malignant Primary Brain and Other CNS Tumors by Central Cancer Registry, CBTRUS Statistical Report: US Cancer Statistics - NPCR and SEER, 2014–2018.

**Fig. 14**
Incidence Rate Ratios by Race (A- Whites:Blacks and B- Whites:Asian Or Pacific Islanders [API]) for Selected Primary Brain and Other CNS Tumor Histologies, CBTRUS Statistical Report: US Cancer Statistics - NPCR and SEER, 2014–2018.

**Fig. 15.**
Distribution^a in Children and Adolescents (Age 0–19 Years) of All Primary Brain and CNS Tumors (Five-Year Total=25,485; Annual Average Cases=5,097) by A) Site and B) Histology, CBTRUS Statistical Report: US Cancer Statistics - NPCR and SEER, 2014–2018.

**Fig. 16.**
Distribution^a in Children and Adolescents (Age 0–14 Years) of All Primary Brain and CNS Tumors (Five-Year Total=17,802; Annual Average Cases=3,560) by A) Site and B) Histology, CBTRUS Statistical Report: US Cancer Statistics - NPCR and SEER, 2014–2018.

**Fig. 17**
Distribution^a in Children and Adolescents (Age 15–19 Years) of All Primary Brain and CNS Tumors (Five-Year Total=7,683; Annual Average Cases=1,537) by A) Site and B) Histology, CBTRUS Statistical Report: US Cancer Statistics - NPCR and SEER, 2014–2018.

**Fig. 18**
Average Annual Age-Adjusted Mortality Rates^a for Malignant Primary Brain and Other CNS Tumors by Central Cancer Registry, CBTRUS Statistical Report: NVSS, 2014–2018.

**Fig. 19**
A) Kaplan-Meier Survival Curves for the Five Most Common Histologies within Age Group at Diagnosis (Age 0–14, 15–39 and 40+) and B) Hazard Ratios And 95% Confidence Intervals for Sex, Age at Diagnosis, Race, and Ethnicity for the Five Most Common Histologies Overall, National, Data provided by CDC’s National Program of Cancer Registries, 2001–2017.

**Fig. 20.**
Distribution^a in Adolescents and Young Adults^b (Age 15–39 Years) of All Primary Brain and Other CNS Tumors (Five-Year Total=62,515; Annual Average Cases=12,503) by A) Site and B) Histology, CBTRUS Statistical Report: US Cancer Statistics - NPCR and SEER, 2014–2018.

**Fig. 21.**
Distribution^a of Primary Spinal Cord, Spinal Meninges, and Cauda Equina Tumors by Histology in A) Children and Adolescents (Age 0–19 Years, Five-Year Total=1,433; Annual Average Cases=287) and B) Adults (Age 20+ Years, Five-Year Total=18,822; Annual Average Cases=3,764), CBTRUS Statistical Report: US Cancer Statistics - NPCR and SEER, 2014–2018.

**Fig. 22**
Annual Age-Adjusted Incidence Rates of All Primary Brain and Other CNS Tumors, and Incidence Trends by Behavior and Age Group at Diagnosis, CBTRUS Statistical Report: US Cancer Statistics - NPCR and SEER, 2000–2018 (varying).

**Fig. 23**
Annual Age-Adjusted Incidence Rates of Primary Brain and Other CNS Gliomas, and Incidence Trends by Age Group at Diagnosis, CBTRUS Statistical Report: US Cancer Statistics - NPCR and SEER, 2000–2018.

**Fig. 24**
Annual Age-Adjusted Incidence Rates of Primary Brain and Other CNS Tumors, and Incidence Trends by Histology for Selected A) Non-Malignant and B) Malignant Histologies, CBTRUS Statistical Report: US Cancer Statistics - NPCR and SEER, 2000–2018 (varying).

See this image and copyright information in PMC

Cited by

Multi-omics and pharmacological characterization of patient-derived glioma cell lines.
Wu M, Wang T, Ji N, Lu T, Yuan R, Wu L, Zhang J, Li M, Cao P, Zhao J, Li G, Li J, Li Y, Tang Y, Gao Z, Wang X, Cheng W, Ge M, Cui G, Li R, Wu A, You Y, Zhang W, Wang Q, Chen J.Wu M, et al.Nat Commun. 2024 Aug 8;15(1):6740. doi: 10.1038/s41467-024-51214-y.Nat Commun. 2024.PMID:39112531Free PMC article.
Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments.
Feldman L.Feldman L.Front Immunol. 2024 Jun 26;15:1384249. doi: 10.3389/fimmu.2024.1384249. eCollection 2024.Front Immunol. 2024.PMID:38994360Free PMC article.Review.
Systemic inflammatory markers and volume of enhancing tissue on post-contrast T1w MRI images in differentiating true tumor progression from pseudoprogression in high-grade glioma.
Satragno C, Schiavetti I, Cella E, Picichè F, Falcitano L, Resaz M, Truffelli M, Caneva S, Mattioli P, Esposito D, Ginulla A, Scaffidi C, Fiaschi P, D'Andrea A, Bianconi A, Zona G, Barletta L, Roccatagliata L, Castellan L, Morbelli S, Bauckneht M, Donegani I, Nozza P, Arnaldi D, Vidano G, Gianelli F, Barra S, Bennicelli E, Belgioia L; disease management team on Neuroncology of IRCCS Ospedale Policlinico San Martino.Satragno C, et al.Clin Transl Radiat Oncol. 2024 Aug 30;49:100849. doi: 10.1016/j.ctro.2024.100849. eCollection 2024 Nov.Clin Transl Radiat Oncol. 2024.PMID:39318678Free PMC article.
Human allogenic γδ T cells kill patient-derived glioblastoma cells expressing high levels of DNAM-1 ligands.
Choi H, Lee Y, Park SA, Lee JH, Park J, Park JH, Lee HK, Kim TG, Jeun SS, Ahn S.Choi H, et al.Oncoimmunology. 2022 Oct 30;11(1):2138152. doi: 10.1080/2162402X.2022.2138152. eCollection 2022.Oncoimmunology. 2022.PMID:36338147Free PMC article.
Identification of T2W hypointense ring as a novel noninvasive indicator for glioma grade and IDH genotype.
Lu Y, Du N, Fang X, Shu W, Liu W, Xu X, Ye Y, Xiao L, Mao R, Li K, Lin G, Li S.Lu Y, et al.Cancer Imaging. 2024 Jun 28;24(1):80. doi: 10.1186/s40644-024-00726-3.Cancer Imaging. 2024.PMID:38943156Free PMC article.

See all "Cited by" articles

References

1. Kruchko C, Ostrom QT, Gittleman H, Barnholtz-Sloan JS. The CBTRUS story: providing accurate population-based statistics on brain and other central nervous system tumors for everyone. Neuro Oncol. 2018;20(3):295–298. - PMC - PubMed
1. Louis DN OH, Wiestler OD, Cavanee WK, ed WHO Classification of Tumours of the Central Nervous System. Lyon, France: International Agency for Research on Cancer; 2016.
1. Centers for Disease Control and Prevention (CDC). National Program of Cancer Registries Cancer Surveillance System Rationale and Approach.1999;http://www.cdc.gov/cancer/npcr/pdf/npcr_css.pdf. Accessed July 21, 2020.
1. Wiśniewski JR, Zougman A, Nagaraj N, Mann M. Universal sample preparation method for proteome analysis. Nat Methods. 2009;6(5):359–362. - PubMed
1. Benign Brain Tumor Cancer Registries Amendment Act, 107th Cong. § 260 (2002).http://www.gpo.gov/fdsys/pkg/PLAW-107publ260/pdf/PLAW-107publ260.pdf. Accessed July 21, 2020.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Related information

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information

Movatterモバイル変換

Account

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Full text links

Actions

Share

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018

Affiliations

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018

Authors

Affiliations

Abstract

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical